Indianapolis, Indiana, USA – February 8, 2025: Tirzepatide is an antidiabetic medication used for … More
CVS Health last Thursday announced that its pharmacy benefit manager division will drop Eli Lilly’s Zepbound from its preferred formulary list starting July 1, 2025. Instead, CVS will prioritize coverage of Wegovy, a competing GLP-1 medication produced by Novo Nordisk.
The move is another skirmish in a broader set of…
Continue Reading
News Source: www.forbes.com
Leave a Reply